Last updated: 10/23/2026 15:00:14
Extended Access of Momelotinib in Adults with Myelofibrosis
GSK study ID
219627
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Trial status
Active, not recruiting
Active, not recruiting
Trial overview
Official title: Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Trial description: This is an extended-access, long-term safety study for participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF) who have not experienced progression of disease and who have tolerated momelotinib (MMB) treatment while participating in previous MMB clinical trials (GS-US-352-0101 [NCT01969838], GS-US-352-1214 [NCT02101268], GS-US-352-1154 [NCT02124746] and SRA-MMB-301 [NCT04173494]). Participants in all cohorts continuing MMB treatment will discontinue MMB from the previous study and initiate MMB in this study at the same dose they were receiving in the previous study. Following the final data cut-off date, the study may move into the post analysis continuation of treatment (PACT) phase in which participants will continue to receive MMB and will be monitored and receive follow-up care in accordance with standard local clinical practice.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:
Number of Participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) by severity
Timeframe: From study start until each participant transitions to PACT (up to approximately 556 weeks)
Secondary outcomes:
Overall survival (OS)
Timeframe: From the start of the study drug until the date of death due to any cause or database lock, whichever comes first (up to approximately 556 weeks)
Leukemia free survival (LFS)
Timeframe: From the start of the study drug until the date of any evidence of leukemic transformation and/or death due to any cause or database lock, whichever comes first (up to approximately 556 weeks)
Interventions:
Drug: Momelotinib
Enrollment:
237
Primary completion date:
2026-11-12
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
- Currently enrolled in Studies GS-US-352-0101, GS-US-352-1214, GS-US-352-1154, or SRA-MMB-301
- Did not discontinue treatment with MMB for any reason while enrolled in Studies GS US 352-0101, GS-US-352-1214, GS-US-352-1154, or SRA-MMB-301
- Known hypersensitivity to MMB, its metabolites, or formulation excipients
- Incomplete recovery from major surgery prior to Day 1 of this study
Inclusion and exclusion criteria
Inclusion criteria:
- Currently enrolled in Studies GS-US-352-0101, GS-US-352-1214, GS-US-352-1154, or SRA-MMB-301
- Did not discontinue treatment with MMB for any reason while enrolled in Studies GS US 352-0101, GS-US-352-1214, GS-US-352-1154, or SRA-MMB-301
- A negative serum or urine pregnancy test is required for female participants of childbearing potential
- Female participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
- Any Grade 3 or 4 (common terminology criteria for adverse events [CTCAE] Version 4.03) non-hematologic toxicity in the prior study that the Investigator considers related to previous MMB use must have resolved, reverted to Grade 1, or reverted to Baseline within the 30 days from last MMB administration to Day 1 of this study
- Any AE requiring MMB interruption during the prior study must have resolved, reverted to Grade 1, or reverted to Baseline within the 30 days from last MMB administration to Day 1 of this study
- Ability and agreement to attend protocol-specified visits at the study site
- Able to comprehend and willing to sign the informed consent form
Exclusion criteria:
- Known hypersensitivity to MMB, its metabolites, or formulation excipients
- Incomplete recovery from major surgery prior to Day 1 of this study
- Pregnant or lactating females
- Presence of greater than or equal to (>=) Grade 3 (CTCAE Version 4.03) peripheral neuropathy
- Known positive status for human immunodeficiency virus (HIV)
- Known chronic active or acute viral hepatitis A, B, or C infection
Trial location(s)
Location
GSK Investigational Site
Baltimore, MD, United States, 21229-5299
Status
Study Complete
Location
GSK Investigational Site
Jacksonville, FL, United States, 32224-1865
Status
Study Complete
Location
GSK Investigational Site
Rochester, MN, United States, 55905-0001
Status
Study Complete
Location
GSK Investigational Site
Stanford, CA, United States, 94305-5821
Status
Study Complete
Study documents
No study documents available.
Results overview
Study Results yet to be posted
Recruitment status
Active, not recruiting
Actual primary completion date
Not applicable
Actual study completion date
Not applicable
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website